Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against OPKO Health, Microchip Technology, and Cocrystal and Encourages Investors to Contact the Firm

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of OPKO Health, Inc., Microchip Technology Incorporated, and Cocrystal Pharma, Inc.  Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.  

OPKO Health, Inc. (OPK)

Class Period: September 26, 2013 - September 7, 2018

Lead Plaintiff Deadline: November 13, 2018

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) OPKO and its Chairman and Chief Executive Officer, Phillip Frost, were engaged in a pump-and-dump scheme with several other individuals and companies in their investments in several penny stocks; (2) this illicit scheme would result in governmental scrutiny including from the SEC; and (3) as a result, defendants’ statements about OPKO’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the OPKO class action go to: http://bespc.com/opk/.

Microchip Technology Incorporated (MCHP)

Class Period:   March 2, 2018 - August 9, 2018

Lead Plaintiff Deadline: November 16, 2018

The complaint alleges that throughout the Class Period, defendants represented that the Microsemi acquisition would be “immediately accretive” by increasing Microchip’s earnings per share as it “will add further operational and customer scale to Microchip.”  Microchip’s CEO Steven Sanghi represented that the “deal is accretive on day one without doing anything, without any synergy,” and was “strategically and financially, a very compelling transaction.”

To learn more about the Microchip class action go to:  https://bespc.com/mchp /.

Cocrystal Pharma, Inc. (COCP)

Class Period: September 23, 2013 - September 7, 2018

Lead Plaintiff Deadline: November 18, 2018

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Cocrystal class action go to: http://bespc.com/cocrystal/.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com